ImmunoCellular Therapeutics, a clinical-stage biotechnology company based in Calabasas, California, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidates includes ICT-107, a dendritic cell (DC) vaccine that completed phase 2 testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. For more information, visit the company’s website at www.imuc.com